Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

The aim of this study is to compare the effectiveness and tolerability of two conditioning chemotherapies prior to allogeneic stem cell transplantation. The following will also be investigated: * Survival * Remission and Relapse rate * Engraftment or graft failure * Graft versus Host Disease (GvHD)

Trial Details

NCT ID
NCT07025824
Phase
PHASE2
Sponsor
Technische Universität Dresden
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Treosulfan (Treo)
  • Melphalan (Mel)
  • Fludarabine (Flud)
Locations (sample)
  • Aachen, Germany|50.77664,6.08342
  • Augsburg, Germany|48.37154,10.89851
  • Berlin, Germany|52.52437,13.41053
  • Chemnitz, Germany|50.8357,12.92922
  • Cologne, Germany|50.93333,6.95

Key Eligibility Criteria

  • Informed consent signed by the patient capable of giving
  • Patient scheduled for allogeneic transplantation within the next 3 weeks
  • Age ≥ 18 years
  • AML or MDS according to WHO with indication for allogeneic HCT:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →